Researchers discuss challenges to developing broadly protective HIV vaccines
September 7, 2011 in HIV & AIDSThe human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not produced in an efficient or timely enough fashion in HIV-infected individuals to effectively block progression of infection, appearing only after a person has been infected with HIV for at least one year -- by which time the virus has fully established itself within the body. In a Perspective article appearing this week in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, assert that a key research goal is to develop HIV vaccines that prevent HIV infection by inducing more effective immune responses than those that occur naturally.
In their article, the authors examine the challenges of developing HIV vaccines that can effectively induce these broadly neutralizing antibodies. Specifically, they describe work under way to design structure-based HIV vaccines, as well as efforts to gain a better understanding of the evolutionary processes that human B cells undergo to produce broadly neutralizing HIV antibodies. The authors conclude that the availability of new research tools, together with the increased understanding of the human immune response to HIV, make them optimistic that an HIV vaccine that provides significant protection against acquisition of HIV infection can be achieved.
More information: MI Johnston and AS Fauci. HIV Vaccine Development – Improving on Natural Immunity. New England Journal of Medicine DOI: 10.1056/NEJMp1107621 (2011).
Provided by National Institutes of Health
-
New strategy proposed for designing antibody-based HIV vaccine
Jun 14, 2009 |
not rated yet |
0
-
New technology opens gateway to studying HIV-specific neutralizing antibodies
Mar 16, 2009 |
not rated yet |
0
-
Researchers report on the early development of anti-HIV neutralizing antibodies
Jan 14, 2011 |
not rated yet |
0
-
Exhausted B cells fail to fight HIV
Jul 14, 2008 |
not rated yet |
0
-
Exhausted B cells hamper immune response to HIV
Jul 14, 2008 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
21 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients
The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) ...
HIV & AIDS
May 23, 2012 |
not rated yet |
0
Newly discovered breast milk antibodies help neutralize HIV
Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, ...
HIV & AIDS
May 22, 2012 |
5 / 5 (3) |
1
|
Reactions to HIV drug have autoimmune cause, reports AIDS journal
Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according ...
HIV & AIDS
May 22, 2012 |
5 / 5 (1) |
0
Is the U.S. ready for home HIV tests?
At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?
HIV & AIDS
May 21, 2012 |
not rated yet |
0
|
Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...
HIV & AIDS
May 17, 2012 |
5 / 5 (1) |
0
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Tongue analysis software uses ancient Chinese medicine to warn of disease
For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare
A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...
